HBeAg 양성 만성간염 환자에서 항바이러스 치료 중단 후 지속적인 관해에 대한 예측 인자
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 전백규 | - |
dc.contributor.author | 이세환 | - |
dc.contributor.author | 김홍수 | - |
dc.contributor.author | 김상균 | - |
dc.contributor.author | 김영석 | - |
dc.contributor.author | 김부성 | - |
dc.contributor.author | 정승원 | - |
dc.contributor.author | 장재영 | - |
dc.contributor.author | 김영돈 | - |
dc.contributor.author | 천갑진 | - |
dc.date.accessioned | 2021-08-11T18:45:35Z | - |
dc.date.available | 2021-08-11T18:45:35Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.issn | 2233-6869 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/9902 | - |
dc.description.abstract | Background/Aims: The optimal timing for discontinuing oral antiviral therapy in patients with HBeAg-positive chronic hepatitis B (CHB) is unclear. The aim of our study was to investigate sustained remission after stopping antiviral therapy in patients with HBeAg-positive CHB. Methods: We analyzed the medical records of 58 patients who were HBeAg-positive and had discontinued antiviral therapy. Antiviral therapy was discontinued after HBeAg seroconversion and HBV DNA negativity for 6-12 months with consolidation therapy. Virologic relapse was defined as an increase in serum HBV DNA >2,000 IU/mL. Results: No difference was observed between the virologic non-relapse and virologic relapse groups in baseline HBV DNA level (p=0.441) or duration of seroconversion (p=0.070). Time-to-undetectable HBV DNA during treatment was shorter in the virologic non-relapse group (29 patients) compared to the relapse group (29 patients) (4.9±2.6 vs. 13.2±12.7 months; p<0.01). Cumulative relapse rates were 12.7 in month 3, 32.7 in month 6, 47.3 in month 12, and 52.7% in month 18. We determined by multivariate analysis that the consolidation period (≥18 months, p=0.020) and early virologic response (HBV DNA <20 IU/mL) at six months during antiviral therapy (p=0.017) were significant predictors for sustained remission. Conclusions: A consolidation period of at least 18 months and early virological response at six months during antiviral therapy were associated with sustained remission in patients with HBeAg-positive CHB after treatment. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한소화기학회 | - |
dc.title | HBeAg 양성 만성간염 환자에서 항바이러스 치료 중단 후 지속적인 관해에 대한 예측 인자 | - |
dc.title.alternative | Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.bibliographicCitation | 대한소화기학회지, v.67, no.1, pp 28 - 34 | - |
dc.citation.title | 대한소화기학회지 | - |
dc.citation.volume | 67 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 28 | - |
dc.citation.endPage | 34 | - |
dc.identifier.kciid | ART002076126 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Treatment | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | Discontinuation | - |
dc.subject.keywordAuthor | Remission | - |
dc.subject.keywordAuthor | Relapse | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.